About
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's and other neurodegenerative diseases, and psychiatric disorders; and AL002, a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia. Address: 3500 Lenox Road NE, Atlanta, GA, United States, 30326 Read Less
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative diseases and psychiatric disorders. Its pipeline includes AL001, an ionic cocrystal technology delivering a therapeutic combinati ...Read More
Company Website : https://www.alzamend.com
Address : 3500 Lenox Road NE, Atlanta, GA, United States, 30326
Employees : 3
Fiscal Year End : April
Currency:
USD
Country :
USA